USANA Health Sciences Stock Price, News & Analysis (NYSE:USNA)

USANA Health Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "USNA."

USANA Health Sciences announced that its Board of Directors has authorized a share repurchase plan on Tuesday, October 23rd 2018, which authorizes the company to buyback $150,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 5.9% of its stock through open market purchases. Stock buyback plans are often an indication that the company's management believes its shares are undervalued.

USANA Health Sciences, Inc. (NYSE:USNA) issued its earnings results on Tuesday, July, 23rd. The company reported $0.91 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.93 by $0.02. The company had revenue of $256 million for the quarter, compared to analyst estimates of $254.66 million. USANA Health Sciences had a net margin of 9.68% and a return on equity of 27.22%. The company's quarterly revenue was down 15.1% on a year-over-year basis. During the same period in the previous year, the firm posted $1.36 EPS. View USANA Health Sciences' Earnings History.

USANA Health Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, October 22nd 2019. View Earnings Estimates for USANA Health Sciences.

USANA Health Sciences will be holding an earnings conference call on Tuesday, October 22nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

USANA Health Sciences updated its FY19 earnings guidance on Tuesday, July, 23rd. The company provided earnings per share (EPS) guidance of $3.70-4.10 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.89. The company issued revenue guidance of $1.02-1.06 billion, compared to the consensus revenue estimate of $1.06 billion.

4 brokers have issued 1 year price targets for USANA Health Sciences' stock. Their forecasts range from $65.00 to $75.00. On average, they anticipate USANA Health Sciences' stock price to reach $70.00 in the next year. This suggests a possible upside of 0.1% from the stock's current price. View Analyst Price Targets for USANA Health Sciences.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for USANA Health Sciences in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for USANA Health Sciences.

News articles about USNA stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. USANA Health Sciences earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for USANA Health Sciences.

Some companies that are related to USANA Health Sciences include Estee Lauder Companies (EL), Herbalife Nutrition (HLF), Nu Skin Enterprises (NUS), Inter Parfums (IPAR), Avon Products (AVP), Prestige Consumer Healthcare (PBH), Revlon (REV), Medifast (MED), Nature's Sunshine Products (NATR) and Veru (VERU).

Based on aggregate information from My MarketBeat watchlists, some companies that other USANA Health Sciences investors own include BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Tableau Software (DATA), Allergan (AGN), Novartis (NVS), Exelixis (EXEL), Illumina (ILMN), Intel (INTC), Ionis Pharmaceuticals (IONS) and NVIDIA (NVDA).

USANA Health Sciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include Robeco Institutional Asset Management B.V. (0.49%), Strs Ohio (0.05%), State of Alaska Department of Revenue (0.04%) and Pacer Advisors Inc. (0.03%). Company insiders that own USANA Health Sciences stock include Daniel A Macuga, David Mulham Mulham, Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Global Ltd Gull, Jim Brown, Joshua Foukas, Kevin Guest, Myron W Wentz, Paul A Jones, Robert A Sinnott, Robert Auciaux and Walter Noot. View Institutional Ownership Trends for USANA Health Sciences.

USNA stock was sold by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V.. Company insiders that have sold USANA Health Sciences company stock in the last year include Feng Peng, Frederic J Winssinger, G Doug Iiekking, Gilbert A Fuller, Global Ltd Gull, Joshua Foukas, Kevin Guest, Myron W Wentz, Robert Auciaux and Walter Noot. View Insider Buying and Selling for USANA Health Sciences.

USNA stock was purchased by a variety of institutional investors in the last quarter, including Pacer Advisors Inc., State of Alaska Department of Revenue and Strs Ohio. Company insiders that have bought USANA Health Sciences stock in the last two years include Global Ltd Gull and Myron W Wentz. View Insider Buying and Selling for USANA Health Sciences.

Shares of USNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of USNA stock can currently be purchased for approximately $69.90.

USANA Health Sciences has a market capitalization of $1.56 billion and generates $1.19 billion in revenue each year. The company earns $126.22 million in net income (profit) each year or $5.16 on an earnings per share basis. USANA Health Sciences employs 1,911 workers across the globe.View Additional Information About USANA Health Sciences.

The official website for USANA Health Sciences is http://www.usana.com/.

USANA Health Sciences' mailing address is 3838 West Parkway Blvd, Salt Lake City UT, 84120. The company can be reached via phone at 801-954-7100 or via email at [email protected]